Tivic Health Shareholders Approve Key Proposals for Strategic Transformation

Tivic Health shareholders have approved key proposals for the company's strategic transformation, including the issuance of equity for its exclusive license agreement for Entolimod and Entolasta. Shareholders also approved the issuance of equity in accordance with previously announced financing arrangements.

Tivic Health Systems, Inc. (Nasdaq: TIVC) has seen a significant milestone in its strategic transformation with the approval of key proposals by shareholders at its annual meeting held on June 30, 2025. The proposals, which were crucial for the company’s expansion into biopharmaceutical markets, included the issuance of equity as a form of payment for its exclusive license agreement for Entolimod™ and Entolasta™ [1].

The approved proposals also encompassed the issuance of equity in accordance with previously announced financing arrangements. This move aligns with the company's efforts to secure necessary funds to support its growth and development initiatives [2].

Tivic Health CEO Jennifer Ernst expressed optimism about the company's future, stating, "We have established a strong foundation for Tivic’s expansion into biopharmaceutical markets -- starting with commercialization of Entolimod for two large-market indications. We have already received strong customer interest in Entolimod’s national defense applications as a potential treatment for acute radiation syndrome. We have also secured exclusive rights for its use in the treatment of neutropenia, a market currently estimated to reach nearly $21 billion worldwide by 2032" [1].

Additionally, the company announced significant leadership changes. Lisa Wolf, who has been serving as the Interim Chief Financial Officer for the past nine months, has now assumed the role of permanent Chief Financial Officer. This appointment signifies a continuity in the financial leadership that has been instrumental in supporting the company’s expansion [1]. Concurrently, Blake Gurfein, who had been the Chief Scientific Officer for eight years, will step down from his role and take on a consultant position, continuing to support the Vagus Nerve Stimulation program [1].

Tivic Health Systems, Inc. aims to treat underserved medical conditions through biochemical and bioelectric therapies that modulate patients’ immune system. The company's lead biopharma product candidate, the TLR5 agonist Entolimod™, has been granted Fast Track and Orphan Drug designation by the FDA. The company's bioelectronic program is developing non-invasive medical devices that personalize key stimulation to modulate pathways implicated in prevalent and debilitating diseases [1].

The company’s first FDA-approved product, ClearUP™, is proven to treat sinus pain and pressure and is available through online retailers and commercial distributors [1].

Forward-Looking Statements

The press release contains forward-looking statements that are subject to substantial risks and uncertainties. These statements are based on current expectations and are subject to inherent uncertainties, risks, and assumptions that are difficult to predict. Further, certain forward-looking statements are based on assumptions as to future events that may not prove to be accurate [1].

References:

[1] https://www.businesswire.com/news/home/20250708263695/en/Tivic-Shareholders-Approve-Key-Proposals-in-Support-of-Strategic-Transformation-Lisa-Wolf-Appointed-Permanent-CFO
[2] https://www.morningstar.com/news/business-wire/20250708263695/tivic-shareholders-approve-key-proposals-in-support-of-strategic-transformation-lisa-wolf-appointed-permanent-cfo